The“Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan(CPT-11),Oxaliplatin(LOHP),Continuous Infusion 5-Fluorouracil,and Leucovorin for Colorectal Cancer”

结直肠癌改良三药cmFOLFOXIRI方案临床应用中国专家共识

Colorectal cancer is the second most common malignant tumor in China.The FOLFOXIRI regimen,which combines 5-fluorouracil/leucovorin,oxaliplatin,and irinotecan,is a high-intensity and highly effective chemotherapy regimen.However,the original regimen is poorly tolerated in Chinese patients.In order to promote the standardization and rational application of FOLFOXIRI regimen by clinicians in China,the“Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan(CPT-11),Oxaliplatin(LOHP),Continuous Infusion 5-Fluorouracil,and Leucovorin for Colorectal Cancer”was formulated by the Committee of Colorectal Cancer in Chinese Southwest Oncology Group.Based on the mechanism underlying the combined three drugs and toxicity profile,the dosage of Chinese modified FOLFOXIRI(cmFOLFOXIRI)regimen and the management of adverse reactions are proposed.This consensus recommended that the FOLFOXIRI regimen be used in neoadjuvant,conversion,and palliative therapy for colorectal cancer under specific conditions.This consensus aimed to drive the application of cmFOLFOXIRI in the field of colorectal cancer in order to bring benefits to colorectal cancer patients.

结直肠癌是中国第二高发的恶性肿瘤。由5-FU、奥沙利铂和伊立替康联合的FOLFOXRI三药方案是结直肠癌的一种高强度化疗方案,疗效显著但毒性较大。为了推动中国临床工作者规范合理地应用FOLFOXRI方案,中国南方肿瘤临床研究协会结直肠癌专业委员会牵头制定了本共识。共识从姑息治疗、转化治疗和新辅助治疗三个方面,对FOLFOXIRI方案的临床应用进行了推荐,并基于中国人群特点、三种药物作用机制以及既往研究数据,首次提出了中国版改良FOLFOXRI(cmFLOFOXRI)方案的药物剂量、用法和毒副反应管理,旨在进一步提高我国结直肠癌治疗水平,使患者更多获益。